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Abstract
Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor fibroblast growth factor-inducible
14 (Fn14) have been associated with liver regeneration in vivo. To further investigate the role of this pathway we
examined their expression in human fibrotic liver disease and the effect of pathway deficiency in a murine model of
liver fibrosis. The expression of Fn14 and TWEAK in normal and diseased human and mouse liver tissue and primary
human hepatic stellate cells (HSCs) were investigated by qPCR, western blotting and immunohistochemistry. In
addition, the levels of Fn14 in HSCs following pro-fibrogenic and pro-inflammatory stimuli were assessed and
the effects of exogenous TWEAK on HSCs proliferation and activation were studied in vitro. Carbon tetrachloride
(CCl4) was used to induce acute and chronic liver injury in TWEAK KO mice. Elevated expression of both Fn14
and TWEAK were detected in acute and chronic human liver injury, and co-localized with markers of activated
HSCs. Fn14 levels were low in quiescent HSCs but were significantly induced in activated HSCs, which could be
further enhanced with the profibrogenic cytokine TGF𝛃 in vitro. Stimulation with recombinant TWEAK induced
proliferation but not further HSCs activation. Fn14 gene expression was also significantly up-regulated in CCl4
models of hepatic injury whereas TWEAK KO mice showed reduced levels of liver fibrosis following chronic CCl4
injury. In conclusion, TWEAK/Fn14 interaction leads to the progression of fibrotic liver disease via direct modulation
of HSCs proliferation, making it a potential therapeutic target for liver fibrosis.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Liver fibrosis occurs as a result of excessive accumu-
lation of extracellular matrix (ECM) and is a common
consequence of the majority of chronic liver diseases. It
can progress to cirrhosis, a major cause of liver-related
morbidity and mortality, and in a small but significant
number of cases leads to the development of liver cancer
[1]. Liver myofibroblasts are considered to be a key
regulator of liver fibrogenesis, due to their ability to
produce ECM, proliferate and migrate [2]. They are
not present in healthy livers but accumulate after injury
and are thought to derive primarily from hepatic stellate
cells (HSCs) [3,4]. Gaining a greater understanding
of liver fibrogenesis could aid in the development of
new treatment options for preventing progression to
end-stage cirrhosis.
The TNF family member TNFlike weak inducer
of apoptosis (TWEAK; TNFSF12) is expressed as a
type II transmembrane protein that can be cleaved
proteolytically to generate a soluble protein [5]. In
vitro data have shown that TWEAK may be involved
in several cellular processes, including proliferation,
differentiation and migration [6]. TWEAK signals
through its receptor, fibroblast growth factor-inducible
14 (Fn14; TNFRSF12A). Interactions between TWEAK
and Fn14 have been reported to modulate fibrosis in
several organs, including the heart, kidney, colon and
muscle [7].
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
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In the liver, the signalling and functional responses
of TWEAK and Fn14 have mainly been investigated in
association with liver regeneration in vivo and only to a
limited extent with fibrosis. Fn14 expression is rapidly
up-regulated following liver injury [8–10] and is asso-
ciated with liver progenitor cells (LPCs) [9,11,12],
whereas TWEAK expression has mainly been detected
in liver-derived natural killer cells and macrophages
[9]. LPCs normally expand as a mechanism for liver
regeneration following severe acute and chronic liver
injury, to help replace damaged hepatocytes and biliary
epithelial cells [13]. In vivo studies have demonstrated
that Fn14 KO mice treated with the choline-deficient,
ethionine-supplemented (CDE) diet to induce LPC
proliferation had fewer LPCs compared with their
wild-type (WT) controls [9]. In addition, those mice
also exhibited a decreased fibrogenic response, includ-
ing less deposition of collagen [9]. Similarly, Fn14
KO mice that had subacute liver injury and were fed
the high-fat Lieber deCarli diet supplemented with
2% alcohol displayed defective liver wound-healing
responses, including fewer LPCs and myofibroblasts
and less deposition of collagen [14]. LPCs are thought
to be involved in the expansion of ductular reactive
cells, and evidence has shown that a correlation exists
between the presence of ductular reactions and the
severity of fibrosis [15], supporting a circumstantial
link between TWEAK-mediated LPC proliferation and
fibrogenesis [9,16].
Thus far, it has not been determined whether TWEAK
has effects on myofibroblasts and HSCs. However, the
current findings suggest that TWEAK–Fn14 interaction
might promote liver fibrogenesis; but whether its mode
of action is via HSCs or whether it is through crosstalk
with LPCs is currently unknown. In addition, the expres-
sion and function of TWEAK and Fn14 has not been
investigated extensively in human fibrotic liver disease.
The aims of our study were to: (a) investigate the
expression and localization of TWEAK and Fn14 in
human liver tissue from normal healthy donor organs
and compare with liver tissue taken from patients with
established end-stage disease; (b) determine the expres-
sions and roles of TWEAK and Fn14 in isolated human
HSCs in vitro; and (c) evaluate the role of TWEAK in a
carbon tetrachloride (CCl4) model of acute and chronic
liver injury.
Materials and methods
Human liver tissue
Human liver tissue was obtained with ethical approval
from the liver transplant unit [Queen Elizabeth Hospital
(QEH), Birmingham, UK]. Explanted liver speci-
mens were obtained from consenting patients with
non-alcoholic steatohepatitis (NASH), alcoholic liver
disease (ALD), primary biliary cirrhosis (PBC), primary
sclerosing cholangitis (PSC), autoimmune hepatitis
(AIH) and acute liver failure (ALF). Normal donor livers
surplus to surgical requirements, or as a by-product of
surgical resection, served as normal controls (NL). All
patients gave informed written consent and studies were
approved by the Local Research Ethics Committee
(Reference No. 06/Q2702/61).
Mice
Male 6–8 week-old homozygous TWEAK KO mice
[17], along with their WT controls (Balb/c background),
were given CCl4 via gavage (Sigma-Aldrich; 1ml/kg
dissolved in mineral oil) to induce acute and chronic
liver injury. Mineral oil alone was used as a control. In
the acute models, the mice received one dose of CCl4
and were sacrificed 24, 48, 72 or 96 h after administra-
tion. In the chronic model, the mice were administered
CCl4 once weekly for each of 4 weeks and sacrificed 3
days after the last dose. All animal procedures were con-
ducted in accordance with Cambridge (MA, USA) laws
and the Institutional Animal Care and Use Committee,
UK (Protocol No. 0458–2013).
Isolation of primary human HSCs
Primary human HSCs were isolated and grown as
described previously [18]. Uninvolved liver tissue from
patients undergoing surgical resection for liver malig-
nancy was dissociated by pronase/collagenase digestion
and HSCs separated by buoyancy centrifugation. HSCs
were cultured on plastic dishes, on which cells were
automatically activated. HSC cultures were in some
instances stimulated with optimum concentrations of
recombinant bFGF (0.61 nM), TGFβ1 (0.40 nM), TNFα
(0.57 nM), IFNγ (5.95 nM; PeproTech, London, UK), or
for gene expression studies HSCs were incubated with
TWEAK (0.06–29.4 nM; Biogen, USA) for 24 h.
Light microscopy and immunostaining
Paraffin-embedded mouse liver tissue cut to 3 μm
thickness was stained with haematoxylin and eosin
(H&E), using standard protocols. For immunohis-
tochemical studies, snap-frozen human sections cut
at 5–7 μm thickness were incubated with mouse
anti-Fn14 (3.7 μg/ml; mP4A8) or mouse anti-TWEAK
(3.24 μg/ml; mP2D10; both Biogen) diluted in
TBS/0.1% Tween 20 for 1 h. Staining was detected
with immPRESS anti-mouse secondary antibody and
3,3′-diaminobenzidine (both Vector Laboratories,
Peterborough, UK). The sections were then counter-
stained with haematoxylin (VWR). Negative controls
were performed using matched isotype control antibod-
ies, which uniformly demonstrated no reaction.
For immunofluorescent staining, HSCs were grown
in Ibidi Slide 12 chamber slides and fixed in methanol.
Human sections or fixed HSCs were dual-stained
with anti-Fn14 (mP4A8), anti-TWEAK (mP2D10),
anti-α-smooth muscle actin (α-SMA; 1:50; 1A4; Dako)
anti-vimentin (1:100; V9; eBioscience, Hatfield, UK)
or anti-CK19 (1:200; Ks 19.1; Progen Biotechnik,
Heidelberg, Germany) and fluorophore-labelled
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 239: 109–121
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secondary antibodies (AlexaFluor 488 anti-mouse
and AlexaFluor 546/594 anti-mouse, both 1:500; Life
Technologies). In some instances, sequential staining
was performed as previously described [19]. DAPI
was used as a nuclear counterstain. The slides were
visualized using a Zeiss LSM 510 confocal microscope
(Carl Zeiss, Germany).
Quantification of α-SMA+ and Sox9+ cells
and collagen
For α-SMA and Sox9 quantification, paraffin-embedded
mouse liver sections were stained on an automated
immunostainer (Dako), using a mouse on mouse
ImmPRESS HRP kit (Vector Laboratories) according
to the manufacturer’s instructions, using anti-mouse
α-SMA (1:200; ASM-1; Vector Laboratories) or
anti-rabbit Sox9 (1:500; Millipore) with a Vector
ImmPRESS horseradish peroxidase rabbit secondary
antibody. Ten non-overlapping fields (×20 objective)
from each section were captured using a light micro-
scope (Carl Zeiss) with identical illumination and
exposure. Digital image analysis was performed using
ImageJ software for α-SMA quantification. Sox9+ cells
were counted manually. For collagen quantification,
paraffin-embedded mouse liver sections or snap-frozen
human liver sections were stained with Sirius red, using
a standard protocol. Collagen values were expressed as
the percentage of the total area of a section occupied by
Sirius red staining.
Cell proliferation assay
HSCs were stimulated with recombinant TWEAK
(5.88–58.8 nM; Biogen), or PDGF-BB (0.41 nM;
Miltenyi Biotec, Surrey, UK) for 48 h. A commer-
cially available CyQUANT NF Proliferation Assay
Kit (Life Technologies) was used, according to the
manufacturer’s instructions, to evaluate cell prolifer-
ation. Fluorescence was measured at 480/520 nm on
a Synergy HT plate reader (Bio-Tek). Background
fluorescence was subtracted and data were expressed in
arbitrary units of fluorescent intensity compared to an
unstimulated control. Further methods are described in
supplementary materials and methods online.
Statistical analysis
Results are presented as median with interquartile
range (IQR). Statistical analysis was performed using
the Kruskall–Wallis test, Mann–Whitney U-test or
Spearman correlation co-efficient, using Prism software
(GraphPad, USA); p< 0.05 was considered statistically
significant.
Results
TWEAK and Fn14 are up-regulated in fatty
and immune-mediated liver diseases and in an
experimental model of acute and chronic liver injury
To determine the roles of TWEAK and Fn14 in liver dis-
ease, we first assessed the expression levels of TWEAK
and Fn14 in a variety of human end-stage liver diseases
and ALF. We used liver tissue taken from patients with
ALD and NASH as examples of fatty liver diseases, as
they are associated with steatosis in the liver, which is
largely driven by lifestyle and environmental factors.We
also included liver tissue sampled from patients with
end-stage PBC, PSC and AIH, which were classed as
immune-mediated liver diseases, where the immuno-
logical response might modulate expression levels of
TWEAK and Fn14.
The levels of Fn14 mRNA (TNFRSF12A) were sig-
nificantly increased in immune-mediated liver diseases
(5.26-fold; p< 0.01) and ALF (7.39-fold; p< 0.01)
when compared to normal human livers (Figure 1A).
A modest increase was observed in fatty liver diseases,
although this did not reach significance (2.19-fold;
p= 0.06). Importantly, Fn14 protein levels in fatty
and immune-mediated liver diseases were both ele-
vated compared to normal donor tissue (Figure 1B).
A significant increase of TWEAK mRNA (TNFSF13)
was observed in fatty livers (2.05-fold; p< 0.01) and
immune-mediated liver diseases (1.93-fold; p< 0.05),
whereas TWEAK mRNA levels in ALF were not sig-
nificantly different (2.89-fold; p= 0.13) compared to
normal human livers (Figure 1A). TWEAK protein
levels were significantly increased in immune-mediated
liver diseases (8.49-fold; p< 0.05) and a trend towards
an increase was detected in fatty livers (13.31-fold;
p= 0.057).
The extent of fibrosis in matched tissue sections was
assessed by Sirius red staining as a surrogate marker of
disease progression. The mRNA and protein levels of
both Fn14 and TWEAK positively correlated with the
extent of liver fibrosis, and therefore the extent of hepatic
injury (Supplementary Figure S1).
To further investigate the expression of TWEAK and
Fn14 during liver injury, WTmice were challenged with
CCl4 orally to induce toxic hepatic damage. Analysis
of murine livers following acute hepatic injury revealed
a significant increase in Fn14 mRNA (Tnfrsf12a) (58-,
44-, 33- and six-fold changes at 24, 48, 72 and 96 h
post-CCl4 challenge, respectively) (Figure 1C). In con-
trast, levels of TWEAK mRNA did not differ signifi-
cantly between experimental groups. A similar effect
was observed for a chronic CCl4-induced model of liver
fibrosis, whereFn14mRNAwas up-regulated 3.18-fold,
(p< 0.01), whereas TWEAK mRNA was not elevated
above baseline (Figure 1D).
TWEAK and Fn14 are expressed by myofibroblasts
in fibrotic septa
To determine the localization of Fn14 in human liver dis-
eases, histological samples from NL, NASH and PSC
were stained by immunohistochemistry (Figure 2A).
In normal human liver tissue, Fn14 expression was
low in the portal area and no staining was detected
in the parenchyma. Higher-power imaging of the por-
tal areas localized Fn14 to blood vessels, in particu-
lar smooth muscle cells in the arterial wall, and bile
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 239: 109–121
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Figure 1. TWEAK and Fn14 expression in normal, chronic and acute liver disease in humans and mice. (A) Expression of Fn14 (TNFRSF12A)
and TWEAK (TNFSF12) mRNA was assessed by qPCR in normal livers (n= 6), chronic fatty liver disease (n= 11; ALD n= 5 and NASH n= 6),
chronic immune-mediated liver disease (n= 18; PBC n= 6, PSC n= 6 and AIH n= 6) and ALF (n= 5). Gene expression is shown relative to
GUSB, using the 2–ΔCT method. (B) Representative western blot image of Fn14, TWEAK and β-actin levels in normal livers, chronic fatty liver
diseases and chronic immune-mediated liver diseases: densitometry analysis of Fn14 protein expressed in normal donor livers (n= 3), fatty
liver disease (n= 8; ALD n= 5 and NASH n= 3) and immune-mediated liver disease (n= 9; PBC n= 3, PSC n= 3 and AIH n= 3) normalized
to β-actin expression; densitometry analysis of TWEAK protein expressed in normal donor livers (n= 3), fatty liver disease (n= 4; ALD n= 1
and NASH n= 3) and immune-mediated liver disease (n= 5; PBC n= 3, PSC n= 1 and AIH n= 1) normalized to β-actin expression. (C, D)
Murine Fn14 (Tnfrsf12a) and TWEAK (Tnfsf12) mRNA were analysed in liver tissue from WT animals by qPCR following (C) acute or (D)
chronic CCl4-induced liver injury, or mineral oil control, at the time points indicated; gene expression is shown relative to Rn18s, using the
2–ΔCT method: dashed line, mRNA levels of mineral oil control-treated KO and WT mice; each dot represents one independent sample; data
are shown as median with IQR; statistical significance is represented as *p< 0.05 or **p< 0.01 (Mann–Whitney U-test)
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 239: 109–121
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ducts. Fn14 staining was also present in blood ves-
sels in tissue sections taken from patients with NASH,
and in myofibroblast-like cells within the fibrotic septa
(Figure 2A). Immunofluorescent dual staining of tis-
sue sections confirmed that Fn14 expression (green)
co-localized with α-SMA (red), a common marker for
myofibroblasts and smooth muscle cells, in normal liv-
ers and in tissue from patients with NASH and PSC
(Figure 2B). Samples from patients with NASH and
PSC also demonstrated co-localization of Fn14 (green)
and CK19 (red), a biliary marker that highlights bile
ducts and areas of ductular reactivity (Supplementary
Figure S2).
Expression of TWEAK in normal liver tissue was
weak and limited to the portal region (Figure 3A).
Increased levels of TWEAK were detected in tissue
sections from NASH and PSC patients and localized
to the portal area and fibrotic septa. TWEAK was
associated with spindle-shaped cells consistent with
a myofibroblast phenotype, similar to that seen for
Fn14 in NASH and PSC, and was also detected in
the sinusoids (Figure 3A). To further investigate the
identity of these cells, dual-colour immunofluorescent
staining for TWEAK (green) and α-SMA (red) was
performed in tissue samples from patients with NASH
(Figure 3B), in addition to detection of the HSC and
myofibroblast marker, vimentin (red) and TWEAK
(green), in NASH and ALF samples (Figure 3C).
Co-localization of TWEAK with α-SMA and vimentin
confirmed the expression of TWEAK by hepatic myofi-
broblasts; it also showed co-localization of TWEAK
with HSCs/myofibroblasts in the sinusoids in NASH
livers (Figure 3C).
Hepatic stellate cells express Fn14 in vitro
and proliferate in response to TWEAK stimulation
Imaging studies identified the presence of Fn14+ cells
in the fibrous septa of diseased liver tissue which
had the morphological appearance of myofibroblasts.
Therefore, we wanted to investigate whether HSCs,
the progenitors of myofibroblasts, also expressed Fn14
and how this process may be regulated. Quiescent
HSCs were isolated from healthy donor liver tissue
and plated on plastic to induce activation of the cells
over a period of 14 days. Expression of Fn14 (green)
by HSCs was detected by immunofluorescence by day
3 post-isolation, and after 14 days the cells expressed
α-SMA (red), confirming differentiation into activated
HSCs (Figure 4A). At days 3–6, Fn14 had a perinuclear
distribution that became more diffuse and cytoplasmic
with prolonged culture. We then investigated factors
required for the regulation of Fn14 expression. Fn14
mRNAwas increased in activated HSCs following stim-
ulation with TGFβ1 for 24 h, whereas bFGF, TNFα and
IFNγ had little effect (Figure 4B). Flow-cytometry anal-
ysis revealed that approximately 90% of activated HSCs
had intracellular stores of Fn14 (data not shown). On
average, 36% (±3%) of HSCs expressed Fn14 on the cell
surface (Figure 4C). This was significantly increased
with stimulation by the pro-fibrogenic cytokine TGFβ1
(56± 6.8%; p< 0.05) and, although bFGF enhanced
the proportion of cells expressing Fn14, this did not
achieve significance (57%± 9.3%). Treatment with
TNFα (47%± 2.5%) or IFNγ (37%± 7.9%) had no
effect on Fn14 cell surface expression by HSCs. This
effect was not associated with an increase in the extent
of surface expression/Fn14+ cell, as determined by the
median fluorescent intensity (MFI) (Figure 4C).
We then investigated whether TWEAK could mod-
ulate HSC function. First, we measured endogenous
secreted TWEAK in HSC supernatant to determine
whether these cells contribute to levels of soluble
(s)TWEAK present in the circulation. We found
a median sTWEAK concentration of 25 pg/ml/30
000 cells in culture medium, confirming that HSCs
are a source of this protein in vitro. To determine
whether increased levels of sTWEAK were able to
elicit responses in HSCs, we treated cultures of pri-
mary human HSCs with 100–1000 ng/ml recombinant
human TWEAK; mimicking extensive changes in local
concentrations of TWEAK that might be expected in
disease liver tissue. Consistent with this, treatment of
HSCs with 100 ng/ml TWEAK significantly enhanced
the proliferative potential of HSCs following 48 h
treatment (p< 0.01), a response that was similar to that
observed for the known mitogen PDGF-BB (10 ng/ml).
Higher concentrations of TWEAK did not significantly
increase HSCs proliferation, but equally did not lead
to a reduction in cell number, as might be expected
from TWEAK-induced cell death (Figure 4D). We
then assessed HSC activation following treatment with
TWEAK by measuring the levels of α-SMA (ACTA2)
and collagen 1a1 (COL1A1) mRNA. The expression of
α-SMA mRNA was reduced following TWEAK expo-
sure at 100 and 500 ng/ml compared to untreated HSCs
(p< 0.05), while levels of COL1A1 were unchanged
following TWEAK stimulation at all concentrations
tested (Figure 4E).
TWEAK is critical for liver fibrogenesis following
acute hepatic injury in vivo
To further dissect the functional role of TWEAK in hep-
atic injury and fibrogenesis, TWEAK KO mice, along
with their matched WT controls, were subjected to a
single CCl4 dose and subsequently killed after 72 h.
Following CCl4 administration, TWEAK KO mice had
similar levels of liver injury compared to their WT
controls, as histological examination demonstrated foci
of centrilobular necrosis and inflammation in both KO
and WT mice treated with CCl4 (Figure 5A). Liver
tissue from TWEAK KO mice showed significantly
lower levels of Col1a1 (p< 0.01) and Tgfb1, which
is a key pro-fibrogenic growth factor that promotes
HSCs activation (p< 0.05) (Figure 5B). In addition,
mRNA levels for enzymes involved in matrix remod-
elling, includingMmp2 (p< 0.05) and tissue inhibitor of
metalloproteinase-1 (Timp1; p< 0.05) were reduced in
TWEAK KO mice compared to their WT controls. The
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 239: 109–121
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Figure 2. Fn14 is expressed by myofibroblasts in human liver disease. (A) Representative immunostaining of Fn14 (brown) in human liver
samples from normal donors and patients with chronic end-stage NASH or PSC; red arrowheads, spindle-shaped cells in the fibrotic scar;
red arrows, ductules in foci of ductular reaction; scale bars= 100 μm. (B) Representative confocal images showing localization of Fn14
(green) expressing cells relative to those expressing the myofibroblast/activated HSCs marker α-SMA in tissue samples from normal donors
and patients with NASH or PSC: co-localization of Fn14 and α-SMA resulted in pseudocolour yellow; (inset) digitally enlarged image; blue,
DAPI used as a nuclear counterstain; scale bar= 50 μm; PV, portal vein; HA, hepatic artery; BD, bile duct
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 239: 109–121
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Figure 3. Expression of TWEAK by stromal cells in diseased human liver tissue. (A) Representative immunostaining of TWEAK (brown)
in human liver samples from normal donors and patients with NASH or PSC; red arrowheads, spindle-shaped cells in the fibrotic scar;
scale bars= 100 μm. (B) Representative confocal images showing association of TWEAK expressing cells (green) with those expressing the
fibroblast marker α-SMA (red) in tissue samples from patients with NASH and (C) vimentin (red) in tissue samples from patients with ALF
and NASH; co-localization of TWEAK and α-SMA/vimentin resulted in pseudocolour yellow; (inset) digitally enlarged image; blue, DAPI
used as a nuclear counterstain; scale bar= 50 μm
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 239: 109–121
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Figure 4. HSCs up-regulate Fn14 expression during activation and proliferate in response to TWEAK stimulation in vitro. HSCs were isolated
from normal liver tissue and plated on plastic to initiate activation. (A) Confocal images of Fn14 (green) and α-SMA (red) expression in
HSCs during a 30-day activation period; (inset) digitally enlarged image; blue, DAPI used as a nuclear counterstain; scale bar= 50 μm.
(B, C) Fn14 expression in HSCs following treatment with bFGF, TGFβ1, TNFα or IFNγ for 24 h in vitro was analysed by (B) qPCR, with gene
expression shown as fold change relative to GUSB (n= 4 HSCs isolates), and (C) flow cytometry, expressed as the fraction of Fn14+ cells, and
expression level, as determined by median fluorescent intensity (MFI) (n= 3); HSCs in medium alone served as control; each dot represents
cells from one independent HSCs isolation. (D) HSCs were stimulated with TWEAK (100–1000 ng/ml) or PDGF-BB (10 ng/ml) for 48 h in
vitro and cell numbers were quantified using the CyQuant assay to determine cell proliferation (n= 4–7); each dot represents replicates
from independent HSCs isolations; data are expressed as fold change above untreated control. (E) HSCs were stimulated with increasing
concentrations of TWEAK for 24 h and expression of ACTA2 and COL1A1 was measured by qPCR; gene expression is shown relative to
GUSB, using the 2–ΔCt method (n= 4); each dot represents cells from one independent HSC isolation; data are shown as median with IQR;
statistical significance is represented as *p< 0.05 or **p< 0.01 (Kruskal–Wallis test)
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 239: 109–121
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levels of Acta2 (p= 0.31) and Mmp9 (p= 0.14) mRNA
remained unchanged.
TWEAK KO mice present with reduced liver fibrosis
upon chronic CCl4-treatment
To examine the effect of TWEAK on chronic liver fibro-
sis, TWEAK KO and TWEAK WT mice were treated
weekly with CCl4 for 4 weeks and the extents of liver
injury and fibrosis were analysed. Histological exami-
nation of livers from TWEAK KO and WT mice treated
with CCl4 chronically revealed foci of centrilobular
necrosis and inflammation in addition to bridging necro-
sis between the central veins. The hepatocytes around
the portal tracts were unaffected. Following CCl4 treat-
ment, TWEAK KO mice exhibited reduced areas of
α-SMA and Sirius red staining in the liver compared
to WT control animals (Figure 6A). α-SMA+ cells dis-
played a zonal distribution and Sirius red+ collagen was
present in fibrous septa and portal areas in mice with
CCl4 injury. Image analysis revealed significantly fewer
myofibroblasts (α-SMA+) and reduced collagen deposi-
tion (Sirius red staining) in TWEAK KO animals com-
pared to TWEAK WT mice (Figure 6B); however, no
difference in the number of LPCs and ductular cells was
found, as indicated by the same number of Sox9+ cells
in TWEAK KO and WT mice following CCl4 treatment
(Figure 6C). In addition, TWEAKKOmice had reduced
Mmp2 mRNA levels compared to their WT controls,
similar to that seen for the acute model (Figure 6D). The
abundance of Acta2, Col1a1, Tgfb1, Mmp9 and Timp1
remained unchanged (Figure 6D).
Discussion
Here we have provided evidence for a pivotal role for
TWEAK in the progression of fibrotic liver disease.
Fn14 and TWEAK expression were elevated in chronic
end-stage human liver disease and correlated positively
with the extent of fibrosis. Localization of TWEAK and
Fn14, as revealed by immunohistochemical methods,
demonstrated that liver myofibroblasts can express both
the ligand and the receptor. Furthermore, we demon-
strated expression of Fn14 in quiescent and activated pri-
mary humanHSCs and showed that exogenous TWEAK
induced HSCs proliferation, consistent with a role in
the development of liver fibrosis. The role of TWEAK
as a novel stimulator of liver fibrogenesis in vivo was
evidenced by reduced fibrosis in TWEAK KO animals
subjected to acute and chronic CCl4-induced liver injury.
Fn14 expression has mainly been associated with
LPCs and biliary epithelial cells [9,10,12]. The liver dis-
eases PSC, PBC and AIH are commonly associated with
aberrant ductular regeneration and, consistent with this,
we found increased Fn14 (TNFRSF12A) mRNA and
protein levels and expression of Fn14 associated with
CK19+ ductule-like structures in end-stage liver dis-
ease explants. Furthermore, a significant up-regulation
of Fn14 protein was observed in tissue sections taken
from patients with ALD and NASH, which revealed
the co-expression of Fn14 with α-SMA+ myofibroblasts
in the fibrotic scar. The only known ligand for Fn14
thus far, TWEAK, has been identified in natural killer
cells and macrophages in the liver [9], although to our
knowledge the pattern of TWEAK expression in human
liver tissue has not been studied in depth. We found
that TWEAKwas up-regulated in chronic liver diseases,
and was associated not only with infiltrating leukocytes
but also with HSCs and myofibroblasts. This suggests
that myofibroblasts can express TWEAK or/and Fn14,
which raises the possibility that TWEAK may exert its
function on HSCs in a paracrine/autocrine manner dur-
ing liver injury. Previously published data by Hotta et al
[20] support this hypothesis in a model of acute kid-
ney injury, where TWEAK produced by tubules acted
via an autocrine loop through up-regulation of the Fn14
receptor. Furthermore, it has previously been suggested
that Kupffer cells might express TWEAK [12] and that
depletion of Kupffer cells with clodronate in vivo leads
to a reduction in TWEAK expression in the liver [21].
Therefore, Kupffer cells are likely to be another source
of TWEAKwithin the inflammatory micro-environment
during liver disease.
It is thought that the principal function of TWEAK is
to induce ductal proliferation and LPCs expansionmedi-
ated through Fn14 [8,11,12]. However, we have demon-
strated that HSCs can also express Fn14 and maintain
expression during spontaneous activation on plastic in
vitro. Prior to HSCs activation, as indicated by the detec-
tion of α-SMA on day 14 (Figure 4A), the staining
pattern for Fn14 was perinuclear and thus suggestive
of Golgi/ER accumulation, whereas Fn14 expression
became more diffuse and cytoplasmic following HSCs
activation. Our data are in accordance with a previous
demonstration that Fn14 is present in the Golgi appa-
ratus and that it can be quickly trafficked to and from
the cell surface, undergoing continuous de novo recep-
tor synthesis [22]. Our data demonstrated that Fn14
expression in HSCs was present prior to the expres-
sion of the activation marker α-SMA, suggesting that
Fn14 is regulated by transcription factors that play a role
in early cellular transformation and that Fn14 expres-
sion might be induced during the early stages of fibro-
sis. Enhanced Fn14 expression during cell transforma-
tion has also been demonstrated in the corneal stroma,
where quiescent keratocytes start expressing Fn14 after
injury [23]. As Fn14 expression was enhanced in HSCs
during phenotypic transdifferentiation, we investigated
factors that could augment Fn14 expression. Therefore,
HSCswere treated with cytokines known to induce Fn14
expression in other cell types [24], in addition to those
that have been detected in fibrotic liver tissue, such
as bFGF, TNFα, IFNγ and TGFβ [25]. Stimulation of
HSCs by TGFβ1 led to a significant up-regulation of
Fn14mRNA and protein cell surface expression in acti-
vated HSCs. The pro-inflammatory cytokines TNFα and
IFNγ were less effective in modulating Fn14 expres-
sion, suggesting that pro-fibrogenic cytokines, rather
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Figure 5. TWEAK KO animals show reduced levels of fibrotic mediators following CCl4-induced acute liver injury; TWEAK KO and
corresponding WT mice were injected with a single dose of CCl4 and killed 72 h afterwards. (A) Representative images of H&E staining from
TWEAK KO and WT mice. (B) Digitally enlarged images of H&E staining from TWEAK KO and WT mice. (C) Expression levels of fibrogenic
mediators were analysed by qPCR in CCl4-treated TWEAK KO mice and relevant controls (n= 5–7); gene expression is shown relative to
Gapdh, using the 2–ΔCT method; Data are shown as median with IQR; each dot represents onemouse; statistical significance is represented as
*p< 0.05 or **p< 0.01 (Mann–Whitney U-test); dashed line, mRNA levels of mineral oil control-treated KO andWTmice; scale bar= 200 μm
than pro-inflammatory factors, induce Fn14 expression
and promote cell surface expression in HSCs.
The immunostaining of liver sections showed that
TWEAK can be expressed by myofibroblasts and,
consistent with these results, activated HSCs secreted
low levels of TWEAK into their culture medium,
providing further support for an Fn14–TWEAK
autocrine/paracrine loop. The co-expression of TWEAK
and Fn14 has also been detected on other cell types,
including primary proximal tubular epithelial cells and
human blastoma cell lines [20,26].
During fibrogenesis, HSCs differentiate, proliferate
and produce ECM. We therefore investigated how
TWEAK might affect HSCs function. Our data show
that TWEAK acts as a novel mitogen for human HSCs
but, intriguingly, the expression of ACTA2 (α-SMA)
decreased following TWEAK stimulation. This has
also been demonstrated in keratocytes, where TWEAK
inhibited transformation into myofibroblasts in vitro
[23]. In addition, it has been demonstrated in a num-
ber of other cell types that TWEAK can regulate
proliferation and differentiation. In hepatoblasts, skele-
tal myoblasts and osteoblasts, TWEAK promoted
proliferation but inhibited differentiation [27–29].
Furthermore, our data also demonstrate that TWEAK
stimulation had no effect on collagen synthesis in
HSCs. In contrast, other studies have demonstrated
that TWEAK induces collagen expression in cardiac
fibroblasts via Fn14 [30,31]. TWEAK might therefore
be important in expanding the HSC population, at
which point pro-fibrogenic factors such as TGFβ1 are
required to enhance the differentiation and broader
fibrotic response.
Insights into the role of TWEAK and Fn14 in liver
fibrosis have arisen from experimental models of
ductular reaction and liver regeneration [9,16]. We
therefore investigated the effect of TWEAK in mod-
els of acute and chronic CCl4-induced liver injury
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Figure 6. TWEAK KO mice present with reduced liver fibrosis upon chronic CCl4 treatment: TWEAK KO and WT mice were dosed with CCl4
once weekly for 4 weeks, then killed 3 days after the final dose; Mice treated with mineral oil were used as a control. (A) Representative
images of liver tissue sections stained with H&E (scale bar= 200 μm), α-SMA antibody (scale bar= 100 μm), Sirius red (scale bar= 600 μm)
and Sox9 (scale bar= 50 μm); red arrows, liver progenitor cells. (B) Digital quantification of α-SMA and Sirius red-positive areas, expressed
as percentage area of 10 randomly selected areas/sample or of one whole liver section, respectively (n= 5–7). (C) Average number of
Sox9-positive cells of 10 perivascular areas/sample, presented as fold change to mineral oil treated controls (n= 5–7). (D) Levels of
fibrosis-associated transcripts were analysed by qPCR in chronic CCl4-treated TWEAK KO mice and TWEAK WT mice (n= 7); expression
is shown relative to Rn18s, using the 2–ΔCT method; data are shown as median with IQR; each dot represents one mouse; statistical
significance is represented as **p< 0.01 or ***p< 0.005 (Mann–Whitney U-test); dashed line, mRNA levels of mineral oil control-treated
TWEAK KO and WT mice
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 239: 109–121
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
120 A Wilhelm et al
model primarily associated with fibrosis. Our data
demonstrated that acute and chronic toxic liver damage
resulted in a significant up-regulation of Fn14, whereas
TWEAK mRNA did not change significantly through-
out acute or chronic CCl4 injury. These results were
similar to previously published data in mice on the
CDE diet [9,14]. Our data also showed that TWEAK
KO mice developed less fibrosis following both acute
and chronic CCl4 injury, as demonstrated by significant
reductions in collagen deposition and myofibroblast
activation, clearly demonstrating the role of TWEAK as
a stimulator of liver fibrogenesis in vivo. As TWEAK
has been associated with an expansion of ductular cells
and LPCs in other models [9,11,12], we also investi-
gated whether CCl4-challenged TWEAK KO mice had
reduced numbers of Sox9+ ductular cells compared to
their WT controls. Our data demonstrated that there
was no difference in the number of Sox9+ cells between
KO and WT mice. This further supports our theory
that CCl4-induced fibrosis is mediated through the
interaction of TWEAK and HSCs and is not solely due
to TWEAK-mediated LPCs proliferation that drives
HSCs activation and fibrogenesis.
In conclusion, our findings suggest that TWEAK can
regulate the fibrogenic response following liver injury.
Furthermore TWEAK can induce the expansion of acti-
vated HSCs through an enhanced proliferative response.
Therapies aimed at modulation of TWEAK expression
could therefore be effective modalities for amelioration
of fibrogenic responses during liver injury.
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